vs
Side-by-side financial comparison of Cardio Diagnostics Holdings, Inc. (CDIO) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Cardio Diagnostics Holdings, Inc. is a precision cardiovascular healthcare company that develops and commercializes integrated genetic and epigenetic diagnostic tests for early detection of coronary heart disease, heart failure, and other cardiovascular conditions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, focusing on delivering accessible, personalized cardiovascular care solutions.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.6K | — | ||
| Q3 25 | $2.9K | — | ||
| Q2 25 | $7.5K | — | ||
| Q1 25 | $940 | — | ||
| Q4 24 | $4.5K | — | ||
| Q3 24 | $6.6K | — | ||
| Q2 24 | $7.9K | — | ||
| Q1 24 | $15.9K | — |
| Q4 25 | — | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-1.3M | — | ||
| Q1 24 | $-4.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | — | ||
| Q1 25 | -173463.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -21412.9% | — | ||
| Q2 24 | -16295.6% | — | ||
| Q1 24 | -26105.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | — | ||
| Q1 25 | -173943.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -21467.6% | — | ||
| Q2 24 | -16365.9% | — | ||
| Q1 24 | -26140.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.98 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-0.97 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.73 | — | ||
| Q2 24 | $-1.71 | — | ||
| Q1 24 | $-5.93 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
